Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341201 | 0.89 | MAPT (0.40) | L3MBTL1MAPTHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6351289 | 0.85 | NPSR1 (0.40) | HSD17B10ALDH1A1HPGDMAPK1EGFR | |
| SCHEMBL6339985 | 0.84 | L3MBTL1 (0.43) | L3MBTL1MAPTHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6351972 | 0.82 | MAPT (0.41) | MAPTHSD17B10ALDH1A1SMN1; SMN2THRB | |
| SCHEMBL6342478 | 0.81 | AR (0.40) | MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL6344690 | 0.81 | BTK (0.36) | HSD17B10ALDH1A1HPGDMAPK1EGFR | |
| SCHEMBL6354533 | 0.80 | SMN1; SMN2 (0.43) | L3MBTL1MAPTHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6343219 | 0.78 | L3MBTL1 (0.40) | L3MBTL1MAPTHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6341115 | 0.78 | MEN1 (0.45) | L3MBTL1MAPTHSD17B10ALDH1A1HPGD | |
| SCHEMBL6344842 | 0.77 | SPR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | L3MBTL1 4704/4885MAPT 3408/4885HSD17B10 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.